Summary

Infection Control Market Summary

The global infection control market size was estimated at USD 52.38 billion in 2024, and is projected to reach USD 74.21 billion by 2030, growing at a CAGR of 6.1% from 2025 to 2030. The market is primarily driven by an increasing number of surgical & clinical procedures that require infection prevention.

Technological advancements in infection control have significantly enhanced the ability of healthcare providers to prevent and manage infections. Innovations such as automated disinfection systems, UV light technology, antimicrobial surface coatings, and advanced air filtration systems have demonstrated efficacy in reducing HAIs by up to 30% and is expected to contribute to the market growth. An increase in outsourcing sterilization services and the introduction of advanced sterilizing solutions are further contributing to the growth of the market for infection control. One of the important growth drivers is the increasing number of government initiatives to ensure highly intensive infection prevention. Government organizations are increasingly involved in issuing guidelines to promote awareness and efficient prevention measures globally, which is expected to contribute to market growth throughout the forecast period. For instance, the World Health Organization (WHO) has issued guidelines for preventing and controlling pandemic- and epidemic-prone acute respiratory diseases in healthcare. The guidelines range from standard precautions such as hand hygiene and usage of personal protective equipment to guidelines for disinfection and sterilization.

According to the article published by the National Library of Medicine in May 2024, Acute respiratory infections (ARIs) are a major global health burden, leading to around 4.25 million deaths annually. These infections lead to millions of outpatient visits each year, particularly affecting high-risk groups such as the elderly, young children, and individuals with chronic conditions such as asthma or heart disease.

Diseases such as pneumonia and infections such as bloodstream, urinary tract, surgical site, and MRSA constitute most hospital-acquired infections. Other major healthcare-associated infections (HAIs) include catheter-associated urinary tract infections, ventilator-associated pneumonia, and catheter-related bloodstream. One of the utmost concerns for the market is HAIs, which affect patient recovery; thereby, mortality rates are being significantly impacted globally. According to an article by NIH in April 2023, HAIs are the most common adverse effects in hospitals, leading to serious health risks, increased morbidity and mortality, and higher costs for patients, families, and healthcare systems. HAIs affect about 3.2% of hospitalized patients in the U.S. and 6.5% in the EU, with global prevalence expected to be even higher. This facilitates the need for effective infection prevention and control solutions.

According to a practical guide published by the WHO on preventing hospital-acquired infections, the increase in hospitalization duration with surgical infections was approximately eight days. These prolonged stays are predicted to significantly contribute to the overall costs incurred during the hospitalization period, thus, raising the clinical urgency for adopting infection prevention measures. It is presumed that prolonged hospital stay is also not economical for the hospitals and healthcare payers due to excessive usage of resources to treat the acquired infection. These additional costs are majorly generated through increased usage of drugs, additional diagnostic studies, and laboratory equipment, creating a resource allocation imbalance.

Global Infection Control Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global infection control market on the basis of type, end use, and region:

• Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Equipment
o Disinfectors
o Washers
o Flushes
o Endoscope Reprocessors
o Sterilization Equipment
o Heat Sterilization Equipment
o Low Temperature Sterilization Equipment
o Radiation Sterilization Equipment
o Filtration Sterilization Equipment
o Liquid Sterilization Equipment
o Others
• Services
o Contract Sterilization
o Ethylene Oxide Sterilization
o E-beam Sterilization
o Gamma Sterilization
o Others
o Infectious Waste Disposal
• Consumables
o Infectious Waste Disposal
o Disinfectants
o Sterilization Consumables
o Safety enhanced medical devices
o Personal Protective Equipment
o Others
• End Use Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospitals
• Medical Device Companies
• Clinical Laboratories
• Pharmaceutical Laboratories
• Others
• Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Infection Control Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Infection Control Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Infection Control Market: Pipeline Analysis
Chapter 4. Infection Control Market: Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. Infection Control Market: Type Movement Analysis
4.3. Global Infection Control Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Equipment
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Disinfectors
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Washers
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Flushes
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Endoscope Reprocessors
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Sterilization Equipment
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.2. Heat sterilization equipment
4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.3. Low Temperature Sterilization Equipment
4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.4. Radiation Sterilization Equipment
4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.5. Filtration Sterilization Equipment
4.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.6. Liquid Sterilization Equipment
4.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Services
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Contract Sterilization
4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.2. Ethylene Oxide Sterilization
4.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.3. E-beam Sterilization
4.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.4. Gamma Sterilization
4.5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.5. Others
4.5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Infectious Waste Disposal
4.6. Consumables
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.2. Infectious Waste Disposal
4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.3. Disinfectants
4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4. Sterilization Consumables
4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.5. Personal Protective Equipment
4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.6. Others
4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Infection Control Market: End Use Estimates & Trend Analysis
5.1. End Use Segment Dashboard
5.2. Infection Control Market: End Use Movement Analysis
5.3. Global Infection Control Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Hospitals
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Medical Device Companies
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Clinical Laboratories
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Pharmaceutical Laboratories
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Others
5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Infection Control Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Infection Control Market by Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Mexico
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. France
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Italy
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. Spain
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Norway
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key country dynamics
6.5.7.2. Regulatory framework/ reimbursement structure
6.5.7.3. Competitive scenario
6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key country dynamics
6.5.8.2. Regulatory framework/ reimbursement structure
6.5.8.3. Competitive scenario
6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Australia
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Thailand
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Argentina
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key country dynamics
6.8.4.2. Regulatory framework/ reimbursement structure
6.8.4.3. Competitive scenario
6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. 3M
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Belimed AG
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. O&M Halyard or its affiliates.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. GETINGE AB (publ) Corporate
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. ASP
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. MATACHANA
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Sterigenics U.S., LLC - A Sotera Health company
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. MMM Group
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Medivators Inc.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. STERIS.
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Midmark Corporation.
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. W&H
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives